NanoScan Offers Breakthrough Nanoparticulate Contrast Agent for Sale

NORRISTOWN, Pa., Oct. 25, 2019 /PRNewswire-PRWeb/ -- NanoScan Imaging LLC ("NanoScan") announced today the sale of its inventory of N1177 iodinated nanoparticulate, plus various intellectual property and know-how assets. Chris Finn, Principal of the advisory firm Alternotio announced that NanoScan has retained Alternotio to sell the assets using a sealed bid sales process on December 17, 2019.

N1177 was originally developed as a breakthrough contrast agent for the in vivo diagnostic pharmaceutical market. Unlike the currently available water-soluble iodinated x-ray contrast agents, N1177 is eliminated primarily via the liver, not the kidney. As a result, the kidneys are spared a potentially harmful insult. In addition to offering improved safety, especially for renally-compromised patients, N1177 offers potentially improved image quality and extended imaging time with less radiation exposure compared to other currently available contrast agents. N1177's potential has been established by extensive preclinical investigations and its safety via various Phase I and early Phase II clinical trials.

Assets included in the sale include 25 kg of the N1177 API (Active Pharmaceutical Ingredient); Japanese patent JP5574961B2 (covering compositions and methods for angiographic imaging optimized for intravenous administration); studies, files and reports associated with the approved N1177 Investigational New Drug (IND) application; and Drug Master File (DMF). A portion of the N1177 API will be set aside for purchase by academic research institutions. Additional non confidential information on these assets can be found at: http://www.alternotio.com

The assets will be sold at a sealed bid sale on December 17, 2019, at noon. Parties interested in purchasing any or all of the assets must sign a confidentiality agreement, which can be obtained by contacting Chris Finn at [email protected] or calling +1 (978) 882 - 2586. Negotiated offers are welcome, but any negotiated sale must be concluded prior to opening bids and must conform to the terms set forth for sealed bids.

ABOUT NANOSCAN IMAGING LLC. NanoScan was founded to acquire N1177 from prior corporate owners (including Kodak/Sterling-Winthrop and Nycomed-Amersham) and to continue its development.

About ALTERNOTIO. Alternotio specializes in the sale of non-lead and distressed intellectual property. Alternotio occasionally works with unique tangible assets that have a substantial intellectual property component.

This release was prepared exclusively for the purpose of considering the transaction contemplated herein. This announcement is not an offer, solicitation, commitment or recommendation to buy or sell a security and does not purport to be a complete statement of all material facts. No representations are made as to the accuracy of such statements or projections.

SOURCE NanoScan Imaging LLC